Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a ra...

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial  Nature

Real-World Evidence Confirms Tafasitamab Benefit in R/R DLBCL - CancerNetwork

Real-World Evidence Confirms Tafasitamab Benefit in R/R DLBCL  CancerNetwork

Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma - OncLive

Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma  OncLive

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refrac...

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial  The Lancet

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma...

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma  The ASCO Post

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma - Targeted Oncology

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma  Targeted Oncology

Accord Healthcare Launches Lenalidomide Capsules, Expanding Access to Essential Oncology Therapie...

Accord Healthcare Launches Lenalidomide Capsules, Expanding Access to Essential Oncology Therapies  PR Newswire

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line ...

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line  The American Journal of Managed Care® (AJMC®)

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): ...

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial  The Lancet

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospectiv...

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma  Nature

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in ...

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma  OncLive

Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple My...

Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma  The ASCO Post

Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork

Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leuk...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leukemia  Nature

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL - OncLive

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL  OncLive

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: A...

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses | Blood Cancer Journal  Nature

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma - OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma  OncLive

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with h...

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial  Nature

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions ...

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma  OncLive

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lympho...

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma  OncLive

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymph...

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma  The ASCO Post

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and...

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study | Leukemia  Nature

Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa p...

Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa positivity and cold agglutinin syndrome: a case report  Frontiers

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/...

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Dia...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma  OncLive

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM - Hematology A...

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM  Hematology Advisor

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma - OncLive

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma  OncLive

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma...

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma  OncLive

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymph...

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma  The ASCO Post

Dr Jakubowiak on the ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma - Onc...

Dr Jakubowiak on the ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma  OncLive

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma - ...

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma  OncLive

Isatuximab Plus Lenalidomide, Bortezomib, and Dexamethasone (Isa-RVd) as Induction Therapy in Tra...

Isatuximab Plus Lenalidomide, Bortezomib, and Dexamethasone (Isa-RVd) as Induction Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Primary Analysis of Parallel Phase 2 Studies by the Dana-Farber Cancer Institute (DFCI)  OncLive

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma - OncLive

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma  OncLive

Zanubrutinib + rituximab + lenalidomide in de novo DLBCL: Phase II results - Lymphoma Hub

Zanubrutinib + rituximab + lenalidomide in de novo DLBCL: Phase II results  Lymphoma Hub

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory ...

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma  OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma - OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma  OncLive

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractor...

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma  The ASCO Post

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, New...

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma  OncLive

Daratumumab–lenalidomide–dexamethasone (DRd) vs. lenalidomide–dexamethasone in patients with rela...

Daratumumab–lenalidomide–dexamethasone (DRd) vs. lenalidomide–dexamethasone in patients with relapsed/refractory multiple myeloma — Polish early real-world experience following DRd reimbursement in the B.54 drug program | Piotrowska | Acta Hae  Via Medica Journals

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple My...

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple Myeloma  Cureus

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL - Lymphoma Hub

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL  Lymphoma Hub

EarlyMIND real-world efficacy data: Tafasitamab + lenalidomide in R/R DLBCL - Lymphoma Hub

EarlyMIND real-world efficacy data: Tafasitamab + lenalidomide in R/R DLBCL  Lymphoma Hub

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma  OncLive

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly D...

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma  OncLive

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL - Lymphoma Hub

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL  Lymphoma Hub

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma - Targeted Oncology

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma  Targeted Oncology

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myel...

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma  Pharmacy Times

Frontline Tafasitamab Combo Improves PFS in Newly Diagnosed DLBCL - CancerNetwork

Frontline Tafasitamab Combo Improves PFS in Newly Diagnosed DLBCL  CancerNetwork

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myel...

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myeloma  OncLive

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple ...

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma  Pharmacy Times

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-D...

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-DRd in Italy: A Multi-Criteria Decision Framework  European Medical Journal

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligibl...

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma  OncLive

Lenalidomide-induced type II Kounis syndrome: a case report - Frontiers

Lenalidomide-induced type II Kounis syndrome: a case report  Frontiers

Study Identifies Recommended Lenalidomide Maintenance Dose for Patients with Multiple Myeloma - D...

Study Identifies Recommended Lenalidomide Maintenance Dose for Patients with Multiple Myeloma  Docwire News

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with ...

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Fo...

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma  OncLive

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Mye...

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study  OncLive

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma - The ASCO Post

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma  The ASCO Post

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and...

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation  Nature

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Admini...

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Administration for adult patients with R/R DLBCL  Lymphoma Hub

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - NEJM

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  NEJM

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Fo...

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT  OncLive

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradat...

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation  Nature

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelod...

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial  Nature

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma:...

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial  Nature

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide -...

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide  Nature

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths - The American Journal of Manage...

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths  The American Journal of Managed Care® (AJMC®)

Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma - Targeted Oncology

Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma  Targeted Oncology

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells - Science ...

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells  Science | AAAS

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America - NEJM

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America  NEJM

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma - NEJM

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma  NEJM

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgro...

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study | Leukemia  Nature

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (...

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma | Blood Cancer Journal  Nature

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma  Nature

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma - NEJM

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma  NEJM

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma - NEJM

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma  NEJM

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial  Nature

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transpla...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial  Nature

Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM - CancerNetwork

Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM  CancerNetwork

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using ...

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4  Nature

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-...

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial  Nature

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomi...

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma  Nature

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients - ERS - Eu...

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients  ERS - European Respiratory Society

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - NEJM

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  NEJM

FDA Approves New Use for Lenalidomide in Multiple Myeloma - National Cancer Institute (.gov)

FDA Approves New Use for Lenalidomide in Multiple Myeloma  National Cancer Institute (.gov)

Lenalidomide long-term neurotoxicity - Neurology® Journals

Lenalidomide long-term neurotoxicity  Neurology® Journals

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma - NEJM

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma  NEJM

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide - Science | AAAS

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide  Science | AAAS

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies - CancerNetwork

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies  CancerNetwork

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q)...

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS  OncLive

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide - Nature

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide  Nature

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma - NEJM

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma  NEJM

Daratumumab + Lenalidomide + Low-Dose Dexamethasone for Patients With Multiple Myeloma - Targeted...

Daratumumab + Lenalidomide + Low-Dose Dexamethasone for Patients With Multiple Myeloma  Targeted Oncology

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in ...

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)  Nature